

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**STA Liposomal cytarabine and daunorubicin for untreated
acute myeloid leukaemia**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

One consultee noted that there is no clinical experience of liposomal cytarabine and daunorubicin for people with Wilson's disease or other copper related metabolic disorders. This was not considered to be an equality issue.

A consultee noted that AML incidence correlates with increasing age and this has implications for treatment options and disease related mortality risk. The consultee sent a link to a report looking at the challenges faced by older patients with leukaemia.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The trial evidence available is restricted to a certain age group (60 to 75 years). The committee should discuss whether there are any equality issues surrounding age during its deliberations. Liposomal cytarabine and daunorubicin will be appraised within its marketing authorisation.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No

Approved by Associate Director (name): ...Frances Sutcliffe.....

Date: 20/02/2018